NCT06625671View on ClinicalTrials.gov

A Phase 1 Study of DB-2304 in Healthy Adults and SLE Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

October 4, 2024

Primary Completion Date

March 23, 2026

Study Completion Date

June 5, 2026

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

DB-2304

DB-2304

DRUG

Placebo

Placebo

DRUG

Prednisone

Prednisone

Trial Locations (1)

3004

RECRUITING

Site AUS01-0, Melbourne

All Listed Sponsors

lead

DualityBio Inc.

INDUSTRY